BLRX

Investor Moves

Investor	Portfolio Value	Portfolio Change	Position Change	Avg Buy Price	Current Price
Ken GriffinCitadel Advisors $-171.7K ExitQ1 2026 $172k -- $3.64
Ken GriffinCitadel Advisors $-285.0K TrimQ3 2025 $285k -- $3.64
Ken GriffinCitadel Advisors $-285.0K TrimQ3 2025 $285k -- $3.64

News

seekingalpha.comBioLineRx Ltd. (BLRX) Q1 2026 Earnings Call Transcriptseekingalpha.comMay 27

prnewswire.comBioLineRx Reports First Quarter 2026 Financial Results and Provides Corporate Updateprnewswire.comMay 27

prnewswire.comBioLineRx and Hemispherian AS Highlight New Data on GLIX1 at the American Society of Clinical Oncology (ASCO) 2026 Annual Meetingprnewswire.comMay 22

prnewswire.comBioLineRx to Report First Quarter 2026 Results on May 27, 2026prnewswire.comMay 20

prnewswire.comBioLineRx and Hemispherian Announce New GLIX1 Data Demonstrating Potent Anti-Tumor Effect in Glioblastoma (GBM) Across Multiple In-Vivo Studies, Including a Temozolomide (TMZ)-Resistant Model with Patient-Derived Xenograftsprnewswire.comMay 19

Trade BLRX

About BioLineRx Ltd.

BioLineRx Ltd., an Israeli biopharmaceutical firm established in 2003 and based in Hevel Modi'in, focuses its clinical-stage development efforts primarily on oncology. Their leading investigational product, Motixafortide, a peptide, has successfully concluded pivotal Phase 3 clinical trials for mobilizing stem cells in autologous transplants, and Phase 2a trials targeting pancreatic cancer. This compound is currently progressing through Phase 2 studies for metastatic pancreatic adenocarcinoma and Phase 1b trials for acute respiratory distress syndrome linked to COVID-19 and other viral infections. Additionally, Motixafortide is being investigated for its therapeutic potential in solid tumors and acute myeloid leukemia. The company's pipeline also includes AGI-134, an immuno-oncology agent presently undergoing Phase 1/2a clinical evaluations for various solid tumors. Furthermore, BioLineRx is advancing BL-5010, a custom-designed, proprietary pen-like device intended for the non-surgical removal of skin lesions. BioLineRx maintains strategic alliances, notably a collaboration with MSD in the domain of cancer immunotherapy, and an agreement with MD Anderson Cancer Center to explore Motixafortide combined with KEYTRUDA (pembrolizumab) for pancreatic cancer. They also have a licensing deal with Perrigo Company plc for the over-the-counter sale of BL-5010.

CEO: Philip A. Serlin
IPO Date: Jul 27, 2011

Market Data

Market data refresh is queued when this stock page is viewed.

Valuation

Valuation snapshot is not available yet.

Financials

Financial statement snapshot is not available yet.

Events

EarningsAug 13

EPS est. -0.15